medigraphic.com
ISSN 0188-2198 (Print)

2016, Number 1

<< Back Next >>

Rev Mex Cardiol 2016; 27 (1)

Dobutamine versus levosimendan for patients with acute decompensated heart failure

Miranda-Aquino T, Pérez-Topete SE, Treviño-Frutos RJ, Guerra-Villa MN

Language: English
References: 19
Page: 44-49
PDF size: 222.75 Kb.


ABSTRACT

Introduction: Heart failure remains a highly frequent cause of hospitalization; with a high morbidity and mortality. Objectives: The aim of this study is to compare the 30-day in hospital survival of patients treated with Levosimendan vs. Dobutamine in acute decompensated heart failure. Secondary aims will be to compare the measurement of LVEF before and after inotropic and length of hospital stay. Material and methods: Observational, descriptive, retrospective study. All adult patients were admitted to the Hospital Christus Muguerza Alta Especialidad, with acute decompensated heart failure diagnosis and have required inotropic support in the period January 2013 to September 2015 were collected. Results: 83 patients were included, however only 38 met the inclusion criteria. Of the 38 patients 20 (53%) were prescribed levosimendan and 18 (47%) dobutamine. The average age in both groups was 62.2 years (± 15.6) of levosimendan versus dobutamine 78.8 years (± 10.6) (p = 0.0005). Survival at 30 days was 100% in levosimendan versus 77.8% in dobutamine (p = 0.0274). In days of hospital stay it was 9.3 days (± 5.1) levosimendan and 13.8 days (± 6.5) in dobutamine (p = 0.02). postinotropic LVEF change was 18.3% (± 6.2) levosimendan versus 18.7% (± 9.9) dobutamine (p = 0.88). Conclusions: The use of dobutamine leads to a lower survival to 30 days, in addition to longer hospital stay. However no difference in LVEF values ​​at admission or inotropic post.


REFERENCES

  1. Tamargo J, Caballero R, Gómez R, Barana A, Amorós I et al. Investigational positive inotropic agents for acute heart failure. Cardiovasc Haematol Disord Drug Targets. 2009; 9 (3): 193-205.

  2. Teerlink J, Metra M, Valerio Z, Sabbah H, Cotter G et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev. 2009; 14 (4): 243-253.

  3. Follath F, Yilmaz M, Delgado JF, Parissis JT, Porcher R et al. Clinical presentation, management and oucomes in the acute heart failure global survey of standard treatment (ALARM-HF). Intensive Care Med. 2011; 37 (4): 619-626.

  4. Fanarrow GC, Abraham WT, Albert NM, Gattis WA, Gheorguiade M et al. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J. 2004; 148 (1): 43-51.

  5. Patel MB, Kaplan IV, Patni RN, Levy D, Strom JA et al. Sustained improvement in flow-mediated vasodilation after short- term administration of dobutamine in patients with severe congestive heart failure. Circulation. 1999; 99 (1): 60-64.

  6. Ramahi TM, Longo MD, Cadariu AR, Rohlfs K, Slade M et al. Dobutamine- induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy. Eur Heart J. 2001; 22 (10): 849-856.

  7. Passos LC1, Barbosa AC, Oliveira MG, Santos EG Jr. Is there evidence favoring the use of beta-blockers and dobutamine in acute heart failure? Arq Bras Cardiol. 2013; 100 (2): 190-197.

  8. Parissis JT, Rafouli SP, Paraskevaidis I, Mebazaa A. Levosimendan: from basic science to clinical practice. Heart Fail Rev. 2009; 14 (4): 265-275.

  9. Innes C, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs. 2003; 63 (23): 2661-2671.

  10. Aidonidis G, Kanonidis I, Koutsimanis V, Neumann T, Erber R et al. Efficiency and safety of prolonged levosimendan infusion in patients with acute heart failure. Cardiol Resp Pract. 2011; 2011: 342302.

  11. Zorlu A, Yücel H, Yontar OC, Karahan O, Tandogan I et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012; 98 (6): 537-543.

  12. Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon AC et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessels. 2013; 5 (4): 227-245.

  13. Nieminen M, Brutsaert D, Dickstein K, Drexler H, Follath F et al. EuroHeart Failure Survey II (EHFS II) : a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27 (22): 2715-2736.

  14. Zafrir B, Amir O. Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives. Isr Med Assoc J. 2012; 14 (3): 184-189.

  15. Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M et al. Intravenous Levosimendan vs Dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010; 12 (4): 404-410.

  16. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE et al. Levosimendan vs dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009; 11 (3): 304-311.

  17. Antonini R, Paim L, Anne C. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arq Bras Cardiol. 2010; 95 (2): 230-237.

  18. Mebazaa A, Niemen M, Packer M, Cohen A, Kleber F et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure. JAMA. 2007; 297 (17): 1883-1891.

  19. Rossinen J, Harjola VP, Siirila WK, Lassus J, Melin J et al. The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study. Acute Card Care. 2008; 10 (4): 209-213.




2020     |     www.medigraphic.com